- Home
- FRTT vs LSTA Comparison
FRTT vs LSTA Comparison
Compare FRTT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRTT | LSTA |
|---|---|---|
| Founded | 2005 | 1980 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Misc Health and Biotechnology Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 15.9M |
| IPO Year | 2025 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FRTT | LSTA |
|---|---|---|
| Price | $0.48 | $1.02 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 89.7K |
| Earning Date | 11-14-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.50 | $0.96 |
| 52 Week High | $3.92 | $5.07 |
Technical Indicators
Market Signals| Indicator | FRTT | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 28.08 | 39.86 |
| Support Level | N/A | $0.97 |
| Resistance Level | $1.03 | $1.28 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 1.99 | 38.17 |
Price Performance
Historical ComparisonAbout FRTT Fort Technology Inc. Common Shares
Fort Technology Inc is engaged the identification and evaluation of assets or business with a view to potentially acquire them or an interest therein by an option or any concomitant transaction.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.